For example, motivated by the marked success of an adoptive cellular immunotherapy based on the chimeric antigen receptor (CAR) for treating various malignant tumor types, a research group developed a cytokine-anchored CAR-T (CCAR-T) cell system using chimeric IL-5/CD28/CD3ζ receptors and revealed the targeted killing effect of IL-5-anchored CCAR-T cells on eosinophils in vivo and in vitro, as well as their protective effect on allergic airway inflammation, significantly surpassing the quintessential therapeutic window of current mAb-based treatments in clinical settings (240). Here, CD28 is linked to cancer.